

[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
121 and 118 and 116	5

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

121 and 118 and 116

[Clear](#)**Search History****Today's Date: 4/27/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l21 and l18 and l16	5	L22
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(homocys\$ or hcy\$)	2095	L21
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l19 and l16	1	L20
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l15 and l18	5	L19
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(alkaline)near2(phosphatase)	15232	L18
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l15 and l16	1	L17
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(baba or bromoacetylbenz\$ or caba or chloroacetylbenz\$ or haloacetylbenz\$)	19114	L16
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(cys\$ or homocys\$ or hcy)near3(assay\$ or immunoassay\$)	69	L15
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l11 and (l5 or l6)	0	L14
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l11 and l12	0	L13
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(protect\$).ti.	261657	L12
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(biological)near2(label\$).ti.	48	L11
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	keczer	0	L10
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l8 and (hcy\$ or homocys\$ or cys\$)	0	L9
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l5 or l6	258	L8
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 and l5 and l6	2	L7
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(kurn)near2(nurith)	42	L6
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(ping)near2(liu)	219	L5
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 and (caba or baba)	0	L4
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 and alkylat?	0	L3
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l1 and (hcy or homocys? or cys?)	0	L2
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	(dade)near2(behrling)	328	L1

09/393,574

(FILE 'HOME' ENTERED AT 14:27:03 ON 27 APR 2001)

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:27:36 ON 27 APR 2001

L1 1 S (KECZER, S? OR KECZER S?)/AU,IN
L2 30473 S (LIU, Y? OR LIU Y?)/AU,IN
L3 41 S (DAVALIAN, D? OR DAVALIAN D?)/AU,IN
L4 131 S (KURN, N? OR KURN N?)/AU,IN
L5 561 S (ULLMAN, E? OR ULLMAN E?)/AU,IN
L6 31114 S L1-L5
L7 14 S L6 AND (HOMOCYS? OR HCY?)
L8 9 DUP REM L7 (5 DUPLICATES REMOVED)
L9 1678 S (BROMO OR CHLORO OR BR OR CL OR HALO) (2A) (BENZOIC ACID?)
L10 613 S (CABA OR BABA)
L11 2291 S L9 OR L10
L12 8 S L11 (5A) (PHOSPHAT?)
L13 8 DUP REM L12 (0 DUPLICATES REMOVED)
L14 0 S L11 AND (HOMOCYS? OR HCY?)
L15 32 S L11 AND (CYS? OR ?HOMOCYS? OR HCY?)
L16 19 DUP REM L15 (13 DUPLICATES REMOVED)
L17 9112 S (ASSAY? OR DETECT?) (3A) (CYS? OR ?HOMOCYS? OR HCY?)
L18 1121 S (ALKYLAT?) (3A) (PROTECT?)
L19 0 S L17 AND L18
L20 45359 S (ALKYLAT?) (3A) (AGENT? OR COMPOUND? OR REAGENT?)
L21 407 S ?ACETYL BENZOIC?
L22 613 S CABA OR BABA
L23 46376 S L20-L22
L24 24 S L23 AND L17
L25 12 DUP REM L24 (12 DUPLICATES REMOVED)
L26 70 S ?PHOPHINE?
L27 110591 S ?PHOSPHINE?
L28 110603 S L26 OR L27
L29 351 S L23 AND L28
L30 2 S L29 AND IMMUNOASSAY?
L31 223 S L20 (3A) (PROTECT?)
L32 1 S L29 AND L31
L33 237 S L23 (3A) (PROTECT? OR ENOL PHOSPHAT?)
L34 1 S L33 AND L28
L35 5 S L33 AND COUPL?
L36 3 DUP REM L35 (2 DUPLICATES REMOVED)

=>

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
AN 1995:911305 CAPLUS
DN 124:117041
TI Synthesis of RS-91309-[3H] and 2-pyridone-[4,6-3H]
AU **Keczer, Steve de**; Parnes, Howard
CS Syntex Discovery Research, Palo Alto, CA, 94304, USA
SO Synth. Appl. Isot. Labelled Compd. 1994, Proc. Int. Symp., 5th (1995),
Meeting Date 1994, 101-3. Editor(s): Allen, John; Voges, Rolf.
Publisher:
Wiley, Chichester, UK.
CODEN: 61UMAF
DT Conference
LA English

=> d ab

L5 ANSWER 1 OF 561 CAPLUS COPYRIGHT 2001 ACS
AB Unavailable

=> d his

(FILE 'HOME' ENTERED AT 14:27:03 ON 27 APR 2001)

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:27:36 ON 27
APR 2001

L1 1 S (KECZER, S? OR KECZER S?)/AU,IN
L2 30473 S (LIU, Y? OR LIU Y?)/AU,IN
L3 41 S (DAVALIAN, D? OR DAVALIAN D?)/AU,IN
L4 131 S (KURN, N? OR KURN N?)/AU,IN
L5 561 S (ULLMAN, E? OR ULLMAN E?)/AU,IN

=> s 11-15

L6 31114 (L1 OR L2 OR L3 OR L4 OR L5)

=> s 16 and (homocys? or hcy?)

L7 14 L6 AND (HOMOCYS? OR HCY?)

=> dup rem 17

PROCESSING COMPLETED FOR L7

L8 9 DUP REM L7 (5 DUPLICATES REMOVED)

=> d 1-9

L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2001 ACS
AN 2001:186030 CAPLUS
DN 134:219382
TI Composition and test kit for protecting groups used in biological
labeling
comprising protected alkylating reagent and deprotecting enzyme
IN De **Keczer, Steve**; **Liu, Yen Ping**; **Davalian, Dariush**;
Kurn, Nurith; **Ullman, Edwin F.**
PA Dade Behring Inc., USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001018548	A2	20010315	WO 2000-US22397	20000815
	W: JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1999-393579	A	19990909		

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1

AN 2000:15483 CAPLUS

DN 132:75694

TI Assay for **homocysteine** using cis-1,4-dioxo-2-butene compounds

IN **Ullman, Edwin F.**

PA USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000000821	A1	20000106	WO 1999-US14504	19990625
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9948355	A1	20000117	AU 1999-48355	19990625
PRAI	US 1998-90992	P	19980629		
	WO 1999-US14504	W	19990625		

OS MARPAT 132:75694

RE.CNT 2

RE

(1) Rozzell; US 5885767 A 1999 CAPLUS

(2) Sundrehagen; US 5631127 A 1997 CAPLUS

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2

AN 2000:655948 CAPLUS

DN 133:346678

TI Homogeneous, rapid luminescent oxygen channeling immunoassay (LOCI) for **homocysteine**

AU **Liu, Yen Ping**; De Keczer, Steve; Alexander, Svetlana; Pirio, Marcel; **Davalian, Dariush**; Kurn, Nurith; **Ullman, Edwin F.**

CS Advanced Diagnostics Division, Dade Behring Inc., San Jose, CA, 95161, USA

SO Clin. Chem. (Washington, D. C.) (2000), 46(9), 1506-1507

CODEN: CLCHAU; ISSN: 0009-9147

PB American Association for Clinical Chemistry

DT Journal

LA English

RE.CNT 7

RE

(1) Fiskerstrand, T; Clin Chem 1993, V39, P263 CAPLUS

(2) Guttormsen, A; Clin Chem 1993, V39, P1390 CAPLUS

(3) Jacobsen, D; Clin Chem 1994, V40, P873 CAPLUS

(4) Ueland, P; Clin Chem 1993, V39, P1764 CAPLUS

(5) Ueland, P; J Lab Clin Med 1989, V114, P473 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 3
 AN 2000:497544 CAPLUS
 DN 133:347919
 TI Physiologic concentrations of **homocysteine** inhibit the human
 plasma GSH peroxidase that reduces organic hydroperoxides
 AU Chen, Nengqian; **Liu, Yuxiu**; Greiner, Charles D.; Holtzman,
 Jordan L.
 CS Department of Pharmacology and Medicine, University of Minnesota,
 Minneapolis, MN, USA
 SO J. Lab. Clin. Med. (2000), 136(1), 58-65
 CODEN: JLCMAK; ISSN: 0022-2143
 PB Mosby, Inc.
 DT Journal
 LA English
 RE.CNT 48
 RE
 (2) Anderson, M; J Biol Chem 1980, V255, P9530 CAPLUS
 (3) Arai, M; J Biol Chem 1999, V274, P4924 CAPLUS
 (4) Araki, A; J Chromatogr 1987, V422, P43 CAPLUS
 (6) Blann, A; Atherosclerosis 1995, V116, P191 CAPLUS
 (7) Bowry, V; Proc Natl Acad Sci USA 1992, V89, P10316 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 9 BIOSIS COPYRIGHT 2001 BIOSIS
 AN 1999:447370 BIOSIS
 DN PREV199900447370
 TI **Homocysteine** inhibits plasma GSH peroxidase.
 AU Chen, N.-Q. (1); **Liu, Y.-X.** (1); Greiner, C. D. (1); Holtzman,
 J. L. (1)
 CS (1) Departments of Medicine and Pharmacology, University of Minnesota and
 Laboratory and Medical Services, VA Medical Center, Minneapolis, MN USA
 SO Journal of Investigative Medicine, (Aug., 1999) Vol. 47, No. 7, pp.
 254A.
 Meeting Info.: Meeting of the American Federation for Medical Research,
 Midwestern Regional Chicago, Illinois, USA September 16-18, 1999 American
 Federation for Medical Research
 . ISSN: 1081-5589.
 DT Conference
 LA English

L8 ANSWER 6 OF 9 BIOSIS COPYRIGHT 2001 BIOSIS
 AN 1999:524794 BIOSIS
 DN PREV199900524794
 TI The human plasma GSH-peroxidase which reduces organic hydroperoxides is
 only in the HDL fraction and is inhibited by **homocysteine**.
 AU Holtzman, Jordan L. (1); Chen, Nengqian (1); **Liu, Yuxiu**;
 Greiner, Charles D.
 CS (1) VAMC/Univ. Minn., Minneapolis, MN USA
 SO Circulation, (Oct. 27, 1998) Vol. 98, No. 17 SUPPL., pp. I802.
 Meeting Info.: 71st Scientific Sessions of the American Heart Association
 Dallas, Texas, USA November 8-11, 1998 The American Heart Association
 . ISSN: 0009-7322.
 DT Conference
 LA English

L8 ANSWER 7 OF 9 BIOSIS COPYRIGHT 2001 BIOSIS
 AN 1998:465246 BIOSIS
 DN PREV199800465246

TI The human plasma GSH-peroxidase which reduces organic hydroperoxides is only in the high density lipoprotein fraction and is inhibited by **homocysteine**.
 AU Chen, N.-Q. (1); Liu, Y.-X.; Greiner, C. D.; Holtzman, J. L.
 CS (1) Dep. Med., Univ. Minnesota, Minneapolis, MN USA
 SO Journal of Investigative Medicine, (Sept., 1998) Vol. 46, No. 7, pp. 288A.
 Meeting Info.: Meeting of the American Federation for Medical Research, Midwestern Regional Chicago, Illinois, USA September 17-19, 1998 American Federation for Medical Research
 . ISSN: 1081-5589.
 DT Conference
 LA English

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:710281 CAPLUS
 DN 126:54268
 TI Polymer- versus Silica-Based Separation Media: Elimination of Nonspecific Interactions in the Chiral Recognition Process through Functional Polymer Design
 AU Liu, Yuelong; Svec, Frantisek; Frechet, Jean M. J.; Juneau, Kathy N.
 CS Baker Laboratory, Cornell University, Ithaca, NY, 14853-1301, USA
 SO Anal. Chem. (1997), 69(1), 61-65
 CODEN: ANCHAM; ISSN: 0003-2700
 PB American Chemical Society
 DT Journal
 LA English

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 4
 AN 1996:71220 CAPLUS
 DN 124:111738
 TI Immunoassay for **homocysteine**
 IN Van Atta, Reuel B.; Goodman, Thomas C.; Ullman, Edwin F.
 PA Syntex (USA) Inc., USA
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9530151	A1	19951109	WO 1995-US5201	19950427
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
	RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5478729	A	19951226	US 1994-234456	19940428
	CA 2188752	AA	19951109	CA 1995-2188752	19950427
	AU 9525844	A1	19951129	AU 1995-25844	19950427
	EP 757794	A1	19970212	EP 1995-920371	19950427
	EP 757794	B1	19980819		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
	JP 09512634	T2	19971216	JP 1995-528372	19950427
	ES 2133772	T3	19990916	ES 1995-920371	19950427
PRAI	US 1994-234456		19940428		

WO 1995-US5201

19950427

09/393,579

(FILE 'HOME' ENTERED AT 14:56:17 ON 27 APR 2001)

FILE 'REGISTRY' ENTERED AT 14:56:43 ON 27 APR 2001

	E PHOSPHINE/CN
L1	2 S E3
	E TRIS (CARBOXYETHYL) PHOSPHINE/CN
L2	1 S E3
L3	STRUCTURE UPLOADED
L4	QUE L3
L5	2 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:58:57 ON 27 APR 2001

L6	1 S L5
L7	6132 S L1 OR L2
L8	14087 S (ALKYLAT?) (3A) (AGENT? OR COMPOUND? OR REAGENT?)
L9	329 S ?ACETYLBenzoic?
L10	185 S (BABA OR CABA)
L11	14598 S L8-L10
L12	2 S L7 AND L11

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS

AN 2001:186030 CAPLUS

DN 134:219382

TI Composition and test kit for protecting groups used in biological labeling

comprising protected **alkylating reagent** and deprotecting enzyme

IN De Keczer, Steve; Liu, Yen Ping; Davalian, Dariush; Kurn, Nurith; Ullman, Edwin F.

PA Dade Behring Inc., USA

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001018548	A2	20010315	WO 2000-US22397	20000815
	W: JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1999-393579	A	19990909		

=> d 2 cbib,ab,hit

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS

1994:239584 Document No. 120:239584 Disulfide structures of highly bridged peptides: A new strategy for analysis. Gray, William R. (Dep. Biol., Univ. Utah, Salt Lake City, UT, 84112, USA). Protein Sci., 2(10), 1732-48

(English) 1993. CODEN: PRCIEI. ISSN: 0961-8368.

AB A new approach is described for analyzing disulfide linkage patterns in peptides contg. tightly clustered cystines. Such peptides are very difficult to analyze with traditional strategies, which require that the peptide chain be split between close or adjacent Cys residues.

Water-sol.

tris-(2-carboxyethyl)-phosphine (TCEP) reduced disulfides at pH 3, and partially reduced peptides were purified by HPLC with minimal thiol-disulfide exchange. Alkylation of free thiols, followed by sequencer anal., provided explicit assignment of disulfides that had been reduced. Thiol-disulfide exchange occurred during alkylation of some peptides, but correct deductions were still possible. Alkylation

competed

best with exchange when the peptide soln. was added with rapid mixing to 2.2M iodoacetamide. Variants were developed in which up to three **alkylating agents** were used to label different pairs of thiols, allowing a full assignment in one sequencer anal. Model peptides used included insulin (three bridges, intra- and interchain disulfides; -Cys.cntdot.Cys- pair), endothelin and apamin (two disulfides; -Cys.cntdot.x.cntdot.Cys- pair), conotoxin GI and isomers (two

disulfides;

-Cys.cntdot.Cys- pair), and bacterial enterotoxin (three bridges within

13

residues; two -Cys.cntdot.Cys- pairs). With insulin, all intermediates

in

the redn. pathway were identified; with conotoxin GI, anal. was carried out successfully for all three disulfide isomers. In addn. to these

known

QP 551. P697

structures, the method was applied successfully to the anal. of several previously unsolved structures of similar complexity. Rates of redn. of disulfide bonds varied widely, but most peptides did not show a strongly preferred route for redn.

AB A new approach is described for analyzing disulfide linkage patterns in peptides contg. tightly clustered cystines. Such peptides are very difficult to analyze with traditional strategies, which require that the peptide chain be split between close or adjacent Cys residues.

Water-sol.

tris-(2-carboxyethyl)-phosphine (TCEP) reduced disulfides at pH 3, and partially reduced peptides were purified by HPLC with minimal thiol-disulfide exchange. Alkylation of free thiols, followed by sequencer anal., provided explicit assignment of disulfides that had been reduced. Thiol-disulfide exchange occurred during alkylation of some peptides, but correct deductions were still possible. Alkylation

competed

best with exchange when the peptide soln. was added with rapid mixing to 2.2M iodoacetamide. Variants were developed in which up to three **alkylating agents** were used to label different pairs of thiols, allowing a full assignment in one sequencer anal. Model peptides used included insulin (three bridges, intra- and interchain disulfides; -Cys.cntdot.Cys- pair), endothelin and apamin (two disulfides; -Cys.cntdot.x.cntdot.Cys- pair), conotoxin GI and isomers (two disulfides;

-Cys.cntdot.Cys- pair), and bacterial enterotoxin (three bridges within

13

residues; two -Cys.cntdot.Cys- pairs). With insulin, all intermediates

in

the redn. pathway were identified; with conotoxin GI, anal. was carried out successfully for all three disulfide isomers. In addn. to these

known



structures, the method was applied successfully to the anal. of several previously unsolved structures of similar complexity. Rates of redn. of disulfide bonds varied widely, but most peptides did not show a strongly preferred route for redn.

IT **5961-85-3**, Tris-(2-carboxyethyl)-phosphine

RL: RCT (Reactant)

(redn. by, of disulfide-contg. peptides for linkage pattern anal.)

=>



chain nodes :

7 8 9 10 11 12 13 14 15 16 17

ring nodes :

1 2 3 4 5 6

chain bonds :

2-7 5-10 7-8 7-9 10-11 10-16 11-12 12-13 12-14 12-15 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

7-8 7-9 10-11 11-12 12-13 12-14 12-15

exact bonds :

2-7 5-10 10-16 16-17


normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS
9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS
16:CLASS 17:CLASS

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2001 ACS
RN 329717-21-7 REGISTRY
CN Benzoic acid, 4-[2-bromo-1-(phosphonoxy)ethenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C9 H8 Br O6 P
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2001 ACS
RN 329717-20-6 REGISTRY
CN Benzoic acid, 4-[2-chloro-1-(phosphonoxy)ethenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C9 H8 Cl O6 P
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=>

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AN 2001:186030 CAPLUS

DN 134:219382

TI Composition and test kit for protecting groups used in biological labeling

comprising protected alkylating reagent and deprotecting enzyme

IN De Keczer, Steve; Liu, Yen Ping; Davalian, Dariush; Kurn, Nurith; Ullman, Edwin F.

PA Dade Behring Inc., USA

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2001018548	A2	20010315	WO 2000-US22397	20000815
	W: JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1999-393579	A	19990909		